Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1948 | 2412 | 28.4 | 68% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
7 | 4 | INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY | 1353914 |
220 | 3 | CYTOMEGALOVIRUS//VIROLOGY//JOURNAL OF VIROLOGY | 50388 |
701 | 2 | HERPES ZOSTER//VARICELLA ZOSTER VIRUS//VARICELLA | 12970 |
1948 | 1 | HERPES ZOSTER//POSTHERPETIC NEURALGIA//VARICELLA ZOSTER VIRUS | 2412 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | HERPES ZOSTER | authKW | 3988432 | 22% | 60% | 523 |
2 | POSTHERPETIC NEURALGIA | authKW | 1079068 | 7% | 47% | 180 |
3 | VARICELLA ZOSTER VIRUS | authKW | 673843 | 9% | 23% | 228 |
4 | SHINGLES | authKW | 614960 | 4% | 52% | 93 |
5 | HERPES ZOSTER OPHTHALMICUS | authKW | 587473 | 2% | 79% | 59 |
6 | POST HERPETIC NEURALGIA | authKW | 300181 | 2% | 46% | 52 |
7 | ZOSTER VACCINE | authKW | 230889 | 1% | 79% | 23 |
8 | HERPES ZOSTER VACCINE | authKW | 174191 | 1% | 81% | 17 |
9 | ZOSTER | authKW | 160784 | 1% | 35% | 36 |
10 | ZOSTAVAX | authKW | 158220 | 1% | 83% | 15 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Infectious Diseases | 5306 | 15% | 0% | 350 |
2 | Dermatology | 3766 | 10% | 0% | 239 |
3 | Clinical Neurology | 3292 | 17% | 0% | 415 |
4 | Medicine, General & Internal | 3006 | 17% | 0% | 421 |
5 | Ophthalmology | 1759 | 8% | 0% | 189 |
6 | Immunology | 1470 | 13% | 0% | 323 |
7 | Anesthesiology | 1356 | 5% | 0% | 116 |
8 | Virology | 606 | 4% | 0% | 104 |
9 | Primary Health Care | 563 | 2% | 0% | 39 |
10 | Microbiology | 467 | 7% | 0% | 174 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | AM RYWLIN PATHOL | 25316 | 0% | 100% | 2 |
2 | CHILDRENS HOSP 616 | 25316 | 0% | 100% | 2 |
3 | LATIN AMER HLTH OUTCOMES | 25316 | 0% | 100% | 2 |
4 | VACCINES LATIN AMER CARIBBEAN | 25316 | 0% | 100% | 2 |
5 | PAIN MANAGEMENT CLIN | 23830 | 0% | 21% | 9 |
6 | EVIDENCE BASED MED DERMATOL DEBM | 16876 | 0% | 67% | 2 |
7 | KATEDRA DERMATOVENEROL | 16876 | 0% | 67% | 2 |
8 | STUDY AGING HUMAN DEV GERIATR | 16876 | 0% | 67% | 2 |
9 | SUBDIRECTORATE HLTH PROMOT PREVENT | 16872 | 0% | 33% | 4 |
10 | FOOD SCI PL BIOTECHNOL | 15892 | 0% | 18% | 7 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF INFECTIOUS DISEASES | 4483 | 3% | 0% | 80 |
2 | TRANSPLANT INFECTIOUS DISEASE | 2786 | 1% | 1% | 16 |
3 | PAIN | 2654 | 2% | 1% | 41 |
4 | JOURNAL OF CLINICAL VIROLOGY | 2138 | 1% | 1% | 24 |
5 | NEUROLOGY | 1918 | 2% | 0% | 58 |
6 | HUMAN VACCINES & IMMUNOTHERAPEUTICS | 1892 | 1% | 1% | 16 |
7 | CLINICAL INFECTIOUS DISEASES | 1838 | 2% | 0% | 44 |
8 | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 1595 | 2% | 0% | 40 |
9 | PAIN CLINIC | 1529 | 0% | 2% | 7 |
10 | JOURNAL OF INFECTION | 1418 | 1% | 1% | 21 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | HERPES ZOSTER | 3988432 | 22% | 60% | 523 | Search HERPES+ZOSTER | Search HERPES+ZOSTER |
2 | POSTHERPETIC NEURALGIA | 1079068 | 7% | 47% | 180 | Search POSTHERPETIC+NEURALGIA | Search POSTHERPETIC+NEURALGIA |
3 | VARICELLA ZOSTER VIRUS | 673843 | 9% | 23% | 228 | Search VARICELLA+ZOSTER+VIRUS | Search VARICELLA+ZOSTER+VIRUS |
4 | SHINGLES | 614960 | 4% | 52% | 93 | Search SHINGLES | Search SHINGLES |
5 | HERPES ZOSTER OPHTHALMICUS | 587473 | 2% | 79% | 59 | Search HERPES+ZOSTER+OPHTHALMICUS | Search HERPES+ZOSTER+OPHTHALMICUS |
6 | POST HERPETIC NEURALGIA | 300181 | 2% | 46% | 52 | Search POST+HERPETIC+NEURALGIA | Search POST+HERPETIC+NEURALGIA |
7 | ZOSTER VACCINE | 230889 | 1% | 79% | 23 | Search ZOSTER+VACCINE | Search ZOSTER+VACCINE |
8 | HERPES ZOSTER VACCINE | 174191 | 1% | 81% | 17 | Search HERPES+ZOSTER+VACCINE | Search HERPES+ZOSTER+VACCINE |
9 | ZOSTER | 160784 | 1% | 35% | 36 | Search ZOSTER | Search ZOSTER |
10 | ZOSTAVAX | 158220 | 1% | 83% | 15 | Search ZOSTAVAX | Search ZOSTAVAX |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | KAWAI, K , GEBREMESKEL, BG , ACOSTA, CJ , (2014) SYSTEMATIC REVIEW OF INCIDENCE AND COMPLICATIONS OF HERPES ZOSTER: TOWARDS A GLOBAL PERSPECTIVE.BMJ OPEN. VOL. 4. ISSUE 6. P. - | 88 | 75% | 53 |
2 | FERAHTA, N , ACHEK, I , DUBOURG, J , LANG, PO , (2016) VACCINES AGAINST HERPES ZOSTER: EFFECTIVENESS, SAFETY, AND COST/BENEFIT RATIO.PRESSE MEDICALE. VOL. 45. ISSUE 2. P. 162 -176 | 79 | 94% | 0 |
3 | DWORKIN, RH , JOHNSON, RW , BREUER, J , GNANN, JW , LEVIN, MJ , BACKONJA, M , BETTS, RF , GERSHON, AA , HAANPAA, ML , MCKENDRICK, MW , ET AL (2007) RECOMMENDATIONS FOR THE MANAGEMENT OF HERPES ZOSTER.CLINICAL INFECTIOUS DISEASES. VOL. 44. ISSUE . P. S1 -S26 | 117 | 57% | 182 |
4 | COHEN, EJ , KESSLER, J , (2016) PERSISTENT DILEMMAS IN ZOSTER EYE DISEASE.BRITISH JOURNAL OF OPHTHALMOLOGY. VOL. 100. ISSUE 1. P. 56 -61 | 53 | 90% | 0 |
5 | BADER, MS , (2013) HERPES ZOSTER: DIAGNOSTIC, THERAPEUTIC, AND PREVENTIVE APPROACHES.POSTGRADUATE MEDICINE. VOL. 125. ISSUE 5. P. 78 -91 | 65 | 73% | 7 |
6 | KEATING, GM , (2016) SHINGLES (HERPES ZOSTER) VACCINE (ZOSTAVAX (R)): A REVIEW IN THE PREVENTION OF HERPES ZOSTER AND POSTHERPETIC NEURALGIA.BIODRUGS. VOL. 30. ISSUE 3. P. 243 -254 | 49 | 94% | 0 |
7 | MAGGI, S , GABUTTI, G , FRANCO, E , BONANNI, P , CONVERSANO, M , FERRO, A , LAZZARI, M , ROSSI, A , SCOTTI, S , VITALE, F , ET AL (2015) PREVENTING AND MANAGING HERPES ZOSTER: KEY ACTIONS TO FOSTER HEALTHY AGING.AGING CLINICAL AND EXPERIMENTAL RESEARCH. VOL. 27. ISSUE 1. P. 5 -11 | 51 | 86% | 3 |
8 | FORBES, HJ , THOMAS, SL , SMEETH, L , CLAYTON, T , FARMER, R , BHASKARAN, K , LANGAN, SM , (2016) A SYSTEMATIC REVIEW AND META-ANALYSIS OF RISK FACTORS FOR POSTHERPETIC NEURALGIA.PAIN. VOL. 157. ISSUE 1. P. 30 -54 | 33 | 87% | 9 |
9 | COHEN, EJ , (2015) MANAGEMENT AND PREVENTION OF HERPES ZOSTER OCULAR DISEASE.CORNEA. VOL. 34. ISSUE . P. S3 -S8 | 50 | 91% | 0 |
10 | GATER, A , UHART, M , MCCOOL, R , PREAUD, E , (2015) THE HUMANISTIC, ECONOMIC AND SOCIETAL BURDEN OF HERPES ZOSTER IN EUROPE: A CRITICAL REVIEW.BMC PUBLIC HEALTH. VOL. 15. ISSUE . P. - | 49 | 84% | 5 |
Classes with closest relation at Level 1 |